Pharma: Other News To Note

• Eisai Inc., of Woodcliff Lake, N.J., said the FDA determined that the company has met the agency's written request requirements for pediatric exclusivity for Aciphex (rabreprazole sodium). As a result, Eisai now has gained an additional six months of U.S. market exclusivity for Aciphex, which will expire on Nov. 8, 2013.